Compare KFRC & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | KMDA |
|---|---|---|
| Founded | 1962 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.7M | 488.6M |
| IPO Year | 1996 | 2013 |
| Metric | KFRC | KMDA |
|---|---|---|
| Price | $43.31 | $8.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $39.67 | $14.00 |
| AVG Volume (30 Days) | ★ 322.3K | 33.7K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.42% | 3.08% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,329,007,000.00 | N/A |
| Revenue This Year | $2.78 | $13.94 |
| Revenue Next Year | $4.32 | $9.84 |
| P/E Ratio | $96.28 | ★ $24.59 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.49 | $6.50 |
| 52 Week High | $47.50 | $9.35 |
| Indicator | KFRC | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 70.86 | 49.64 |
| Support Level | $26.60 | $7.96 |
| Resistance Level | $47.48 | $8.40 |
| Average True Range (ATR) | 2.12 | 0.17 |
| MACD | 1.33 | 0.00 |
| Stochastic Oscillator | 75.82 | 45.78 |
Kforce Inc is a solutions firm specializing in technology, finance, accounting, and other professional staffing services. The company operates two business segments: the Technology segment, which provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. The FA segment offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting, business and cost analysis; and taxation and treasury. The majority of revenue is earned through the Technology segment.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.